Moneycontrol PRO
Loans
Loans
HomeNewsBusinessEarningsCipla beats estimates as Q4 net profit zooms 78% to Rs 939 crore

Cipla beats estimates as Q4 net profit zooms 78% to Rs 939 crore

A Moneycontrol poll of eight brokerages pegged the net profit at Rs 891 crore.

May 10, 2024 / 15:38 IST
..

Pharma major Cipla has reported a consolidated net profit of Rs 939 crore for the January to March period, up 79 percent year-on-year (YoY), compared with Rs 525.6 crore in the year-ago period.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Pharma major Cipla on May 10  reported a consolidated net profit of Rs 939 crore for the quarter ended March 2024, making a 78 percent spike over last year's Rs 525.6 crore.

A Moneycontrol poll of eight brokerages pegged the net profit at Rs 891  crore.

Consolidated revenue from operation for the quarter under review stood at Rs 6082 crore, up 4 percent as against Rs 5,793.3 crore in the corresponding period a year ago. A Moneycontrol poll of  brokerages pegged the revenue from operations at Rs 6,224  crore.

At the operating level, EBITDA rose 12 percent to Rs 1316 crore as against Rs 1173 crore last fiscal. EBITDA margin stood at 21.3 percent as compared to 20.5 percent in the same period last fiscal.

The India business grew 7 percent YoY backed by branded prescription and trade generics, the company said.  Revenue in North American region was at $ 226 million up 11 percent YoY supported by continued growth in key differentiated assets as well as base portfolio, the company said.

The R&D expenses for the quarter are higher by 19 percent YoY at Rs 444 crore or 7.2 percent of the revenue, driven by product filing costs and developmental efforts. On a full year basis, the costs were Rs 1,571 crore or 6.2  percent of the revenue.
During the year, cash outflow towards capital expenditure at Cipla was Rs 1,315 crore spent for growth and improving our capacities and capabilities.

Incorporated in 1935, Cipla was promoted by the late Dr KA Hamied and is currently spearheaded by Dr YK Hamied. The promoter group holds a 33.40 percent equity stake in the company as on June 30, 2023. It is engaged in the manufacturing of formulations and APIs, with over 97 percent of the sales being contributed from the formulation segment in FY23.

Cipla has a diversified product portfolio of more than 1,500 drugs, catering to various segments such as anti-infective, cardiac, gynaecology, and gastrointestinal, in over 80 markets across the world.

Shares of the company reacted negatively to the results. Shares were down 1.18 percent in NSE at Rs 1341.90 at 2.56 pm on May 10.

Moneycontrol News
first published: May 10, 2024 02:41 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347